Do analysts rate CEPO or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CEPO or THAR?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cantor Equity Partners N/A N/A -$6.66M -$0.47 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is CEPO or THAR more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Cantor Equity Partners N/A N/A -2.95% Tharimmune N/A -588.45% -264.41%

Do analysts rate TROO or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TROOPS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, TROO or THAR?

Tharimmune has lower revenue, but higher earnings than TROOPS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TROOPS $17.10M 14.22 -$27.91M N/A N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is TROO or THAR more profitable?

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets TROOPS N/A N/A N/A Tharimmune N/A -588.45% -264.41%

Do analysts recommend THAR or TONX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verb Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer THAR or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, THAR or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is THAR or CNTN more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Hillstream Biopharma N/A -31.50% -24.72%

Do analysts prefer HSDT or THAR?

Solana presently has a consensus price target of $3.50, indicating a potential upside of 105.88%. Given Solana's stronger consensus rating and higher probable upside, equities analysts plainly believe Solana is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solana 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HSDT or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Solana -1,427.15% -67.57% -24.09% Tharimmune N/A -588.45% -264.41%

Tharimmune (THAR) Competitors

$1.97 0.00 (0.00%)

As of 08/13/2026

Compare

THAR vs. CEPO, TROO, TONX, CNTN, and HSDT

Should you buy Tharimmune stock or one of its competitors? Tharimmune's main competitors and comparable companies include Cantor Equity Partners (CEPO), TROOPS (TROO), Verb Technology (TONX), Hillstream Biopharma (CNTN), and Solana (HSDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Tharimmune compare to Cantor Equity Partners?

Cantor Equity Partners (NASDAQ:CEPO) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.47	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cantor Equity Partners has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, Cantor Equity Partners had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Cantor Equity Partners and 0 mentions for Tharimmune. Cantor Equity Partners' average media sentiment score of 0.98 beat Tharimmune's score of 0.00 indicating that Cantor Equity Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Cantor Equity Partners	Positive
Tharimmune	Neutral

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cantor Equity Partners	N/A	N/A	-2.95%
Tharimmune	N/A	-588.45%	-264.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cantor Equity Partners beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Tharimmune compare to TROOPS?

TROOPS (NASDAQ:TROO) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TROOPS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are owned by institutional investors. 1.1% of TROOPS shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TROOPS has a beta of 3.49, meaning that its stock price is 249% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, TROOPS had 6 more articles in the media than Tharimmune. MarketBeat recorded 6 mentions for TROOPS and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat TROOPS's score of -0.26 indicating that Tharimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
TROOPS	Neutral
Tharimmune	Neutral

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TROOPS	N/A	N/A	N/A
Tharimmune	N/A	-588.45%	-264.41%

Tharimmune has lower revenue, but higher earnings than TROOPS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TROOPS	$17.10M	14.22	-$27.91M	N/A	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Summary

TROOPS beats Tharimmune on 5 of the 9 factors compared between the two stocks.

How does Tharimmune compare to Verb Technology?

Tharimmune (NASDAQ:THAR) and Verb Technology (NASDAQ:TONX) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Verb Technology had 5 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Verb Technology and 0 mentions for Tharimmune. Verb Technology's average media sentiment score of 0.20 beat Tharimmune's score of 0.00 indicating that Verb Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Verb Technology	Neutral

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 7.2% of Verb Technology shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 21.4% of Verb Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tharimmune has a net margin of 0.00% compared to Verb Technology's net margin of -532.78%. Verb Technology's return on equity of -58.69% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Verb Technology	-532.78%	-58.69%	-57.33%

Tharimmune has higher earnings, but lower revenue than Verb Technology. Verb Technology is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Verb Technology	$12.78M	11.59	-$148.48M	-$2.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verb Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Verb Technology has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Summary

Verb Technology beats Tharimmune on 8 of the 12 factors compared between the two stocks.

How does Tharimmune compare to Hillstream Biopharma?

Tharimmune (NASDAQ:THAR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Hillstream Biopharma's return on equity of -31.50% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

In the previous week, Hillstream Biopharma had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Hillstream Biopharma and 0 mentions for Tharimmune. Hillstream Biopharma's average media sentiment score of 1.89 beat Tharimmune's score of 0.00 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Hillstream Biopharma	Very Positive

Summary

Hillstream Biopharma beats Tharimmune on 7 of the 10 factors compared between the two stocks.

How does Tharimmune compare to Solana?

Solana (NASDAQ:HSDT) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Solana had 7 more articles in the media than Tharimmune. MarketBeat recorded 7 mentions for Solana and 0 mentions for Tharimmune. Solana's average media sentiment score of 0.97 beat Tharimmune's score of 0.00 indicating that Solana is being referred to more favorably in the media.

Company	Overall Sentiment
Solana	Positive
Tharimmune	Neutral

Tharimmune has lower revenue, but higher earnings than Solana. Tharimmune is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	16.49	-$40.89M	-$109.67	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Tharimmune has a net margin of 0.00% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Tharimmune	N/A	-588.45%	-264.41%

Solana has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Solana presently has a consensus price target of $3.50, indicating a potential upside of 105.88%. Given Solana's stronger consensus rating and higher probable upside, equities analysts plainly believe Solana is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.6% of Solana shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Solana beats Tharimmune on 12 of the 16 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$74.33M	$26.81B	$14.09B	$13.05B
Dividend Yield	N/A	5.92%	5.88%	10.72%
P/E Ratio	-0.49	18.68	29.33	25.30
Price / Sales	N/A	402.95	510.18	101.40
Price / Cash	N/A	172.00	39.97	50.75
Price / Book	2.90	3.09	3.70	6.33
Net Income	-$12.20M	$1.09B	$1.31B	$347.70M
7 Day Performance	5.91%	0.64%	0.74%	1.07%
1 Month Performance	-13.22%	-0.54%	1.77%	1.03%
1 Year Performance	49.24%	-11.07%	12.26%	20.77%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	N/A	$1.97 flat	N/A	+49.2%	$74.33M	N/A	N/A	2
CEPO Cantor Equity Partners	0.5466 of 5 stars	$10.65 flat	N/A	-1.4%	$271.58M	N/A	N/A	2	Analyst Forecast
TROO TROOPS	0.1984 of 5 stars	$1.95 -1.0%	N/A	+124.4%	$238.21M	$17.10M	N/A	20	Gap Up
TONX Verb Technology	0.9936 of 5 stars	$2.84 +0.7%	N/A	N/A	$160.55M	$16.73M	N/A	170
CNTN Hillstream Biopharma	0.4197 of 5 stars	$1.86 -2.1%	N/A	N/A	$143.44M	N/A	N/A	2	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. CEPO, TROO, TONX, CNTN, and HSDT

How does Tharimmune compare to Cantor Equity Partners?

Summary

How does Tharimmune compare to TROOPS?

Summary

How does Tharimmune compare to Verb Technology?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Summary

How does Tharimmune compare to Solana?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. CEPO, TROO, TONX, CNTN, and HSDT

How does Tharimmune compare to Cantor Equity Partners?

Which has better earnings and valuation, CEPO or THAR?

Do institutionals & insiders have more ownership in CEPO or THAR?

Which has more risk and volatility, CEPO or THAR?

Does the media favor CEPO or THAR?

Is CEPO or THAR more profitable?

Do analysts rate CEPO or THAR?

Summary

How does Tharimmune compare to TROOPS?

Do analysts rate TROO or THAR?

Do insiders & institutionals have more ownership in TROO or THAR?

Which has more risk & volatility, TROO or THAR?

Does the media favor TROO or THAR?

Is TROO or THAR more profitable?

Which has higher valuation and earnings, TROO or THAR?

Summary

How does Tharimmune compare to Verb Technology?

Does the media refer more to THAR or TONX?

Do institutionals and insiders hold more shares of THAR or TONX?

Is THAR or TONX more profitable?

Which has stronger valuation and earnings, THAR or TONX?

Do analysts recommend THAR or TONX?

Which has more volatility and risk, THAR or TONX?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Is THAR or CNTN more profitable?

Which has more risk & volatility, THAR or CNTN?

Do institutionals & insiders hold more shares of THAR or CNTN?

Do analysts prefer THAR or CNTN?

Which has better earnings & valuation, THAR or CNTN?

Does the media refer more to THAR or CNTN?

Summary

How does Tharimmune compare to Solana?

Does the media prefer HSDT or THAR?

Which has stronger valuation & earnings, HSDT or THAR?

Is HSDT or THAR more profitable?

Which has more risk & volatility, HSDT or THAR?

Do analysts prefer HSDT or THAR?

Do institutionals & insiders believe in HSDT or THAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools